Previous Article | Next Article ![]()
Antimicrobial Agents and Chemotherapy, December 2000, p. 3402-3407, Vol. 44, No. 12
Department of Pharmacology, Yale University School of
Medicine, New Haven, Connecticut 06520
Received 15 March 2000/Returned for modification 25 May
2000/Accepted 25 August 2000
L-Nucleoside analogs are new therapeutic agents for
treatment of chronic hepatitis B. However, their clinical application was limited by the emergence of viral resistance. It is important to
develop a new system to evaluate drug cross-resistance and to test new
agents that may overcome resistant virus. In this report, three cell
lines HepG2-WT10, HepG2-SM1, and HepG2-DM2 are presented; these cell
lines were established by transfection of HepG2 cells with unique fully
functional 1.1× hepatitis B virus (HBV) genomes: wild-type HBV-adr and
its L526M and L526MM550V variants, respectively. We have demonstrated
that these genomes have different susceptibilities to lamivudine
[L(
0066-4804/00/$04.00+0
Copyright © 2000, American Society for Microbiology. All rights reserved.
Characterization of Novel Human Hepatoma Cell Lines with Stable
Hepatitis B Virus Secretion for Evaluating New Compounds against
Lamivudine- and Penciclovir-Resistant Virus
)SddC] and penciclovir (PCV). By examining HBV RNA
transcription, antigen expression, progeny DNA replication, and viral
susceptibilities to L(
)SddC, PCV, and other nucleoside
analogs, it is concluded that the cell lines are able to stably produce
L(
)SddC- and PCV-sensitive and -resistant HBV virions. In
addition, the relative susceptibilities of the wild-type and mutant HBV
produced from the stably transfected cell lines to several anti-HBV
nucleoside analogs were also examined and found to be about the same as
those found by using a transient infection system. PMEA
[9-(2-phosphonylmethoxytehyl)-adenine] and QYL685 are able to
suppress L(
)SddC- and PCV-resistant HBV. In conclusion,
this cell culture system is a novel and useful tool for evaluating
anti-HBV compounds and biologics.
*
Corresponding author. Mailing address: Department of
Pharmacology, Yale University School of Medicine, New Haven, CT 06520. Phone: (203) 785-7119. Fax: (203) 785-7129. E-mail:
cheng.lab{at}yale.edu.
This article has been cited by other articles:
Copyright © 2009 by the American Society for Microbiology. For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»